摘要
目的:了解曲妥珠单抗(Trastuzumab,商品名为赫赛汀)联合白细胞介素-2(IL-2)对肾癌细胞在体外的杀伤抑制作用,同时检测肾癌细胞在药物作用前后人表皮生长因子受体2(HER2)、多药耐药相关蛋白1(MRP1)的表达情况。方法:肾癌细胞系通过细胞培养技术进行培养,用单四唑(MTT)法观察曲妥珠单抗联合IL-2对该细胞系的抑制杀伤效果,进而运用链霉抗生物素-过氧化物酶免疫组化(S-P)法对HER2、MRP1表达进行测定。结果:曲妥珠单抗联合IL-2对肾癌细胞的生长抑制及耐药性呈时间和剂量依赖性。经药物处理后,HER2、MRP1表达明显下降(P<0.05)。结论:曲妥珠单抗能有效地抑制肾癌细胞的生长,对瘤细胞的耐药性也有一定的逆转作用。
Objective: To study the influences of Trastuzumab and IL-2 on human epidermal growth factor receptor-2 ( HER2), muhidrug resistance-associated protein 1 ( MRP1 ) of ACHN in vitro. Methods : ACHN cell line of RCC were cultured by cell culture technique. The tetrazolium-based colorimetric assay was used to evaluate the growth inhibitory effects of trastuzumab and IL-2. S-P method was used to determine the expression of HER2, MRP1 of the cells. Results: Trastuzumab showed the inhibitory effects on growth and multi-drug resistance in RCC from 40μg/L or 24 h in time-effective and dose-dependent manner. After treatment with Trastuzumab and/or IL-2, the expression of HER2, MRP1 genes of RCC was decreased significantly( P 〈 0.05 ). Conclusion: Trastuzumab and IL-2 can inhibit the proliferation of RCC and decrease the expression of HER2, MRP1 in ACHN.
出处
《医学研究生学报》
CAS
2005年第8期686-689,共4页
Journal of Medical Postgraduates
基金
华中科技大学同济医学院科研基金资助项目(批准号:200449)
关键词
人肾癌细胞株
白细胞介素-2
人表皮生长因子受体2
多药耐药相关蛋白1
Human caucasian kidney adenocarcinoma
Interleukin-2
Human epidermal growth factor receptor2
Multidrug resistance-associated protein 1